low absolute neutrophil counts and may occur as idiopathic
entity or as a manifestation of a wide spectrum..
The Kick-off Meeting of the Neutro-NARPS (CA24124) Action will take place
in Brussels, on October 25, 2025, at the COST Association Office.
Network for the Advancement of Neutropenia Research and Patient Support (Neutro-NARPS)
Action Details
– MoU – 033/25
– CSO Approval date – 19/05/2025
– Start date – 24/10/2025
– End date – 23/10/2029
Chronic Neutropenia (CNP) is a rare disorder characterized by persistently low absolute neutrophil counts and may occur as idiopathic entity or as a manifestation of a wide spectrum, mild to life-threatening, congenital or acquired, diseases. The principal challenge of the Network for the Advancement of Neutropenia Research and Patient Support (Neutro-NARPS) is to establish a multi-disciplinary consortium of top-level European and International experts and young investigators with high interest in CNP from the fields of medicine, molecular biology, bioinformatics and computational biology. These partners will work in close collaboration with patient Registries and Organizations, biotech and pharmaceutical companies, the European Haematology Association, and Competent Authorities to bridge the gap between basic research, translational medicine, and clinical practice. The Action’s network will focus on (a) the understanding of the pathogenesis and natural history of CNP, (b) improvement of diagnosis, (c) development and translation to the clinic of novel, repurposed or targeted treatment approaches including gene therapy, and (d) evaluation of the effect of the disease and treatment on patients’ Quality of Life (QoL). Neutro-NARPS envisions elucidating the pathogenetic mechanisms particularly associated with newly recognized CNP entities, investigating the role of nutrition and inflammation on disease initiation and evolution, identifying biomarkers for targeted therapies, and enhancing diagnostic and prognostic precision by applying machine learning (ML) technologies. The Action also aims to facilitate the translation of novel and potentially curative therapies from bench-to-bedside and to improve QoL by developing novel tools for the evaluation of patient reported outcomes (PROs).
Action Of European Cooperation in Science and Technology
How can I participate?
Read the MoU
Read the Action
Description MoU
Main Proposer/Chair
Inform the Main Proposer/Chair of your interest (email)
Apply
Apply to join your Working Groups of interest
Please note
Management Committee nominations are carried out through the COST National Coordinators
Explore Working Groups
Working Group 1
THE ROLE OF INFLAMMATION IN CONGENITAL CNP
Working Group 2
ACQUIRED AND LIKELY-ACQUIRED CNP AND INFLAMMATION
Working Group 3
CNP RISK FACTOR PROFILING AND ML PREDICTIVE MODELING
Working Group 4
DRUG-INDUCED NEUTROPENIAS BY NOVEL THERAPIES
Working Group 5
GENERAL CONCEPT AND DESIGN OF CLINICAL TRIALS
Working Group 6
DEVELOPMENT OF TOOLS FOR EVALUATION OF PROs AND QoL
Our Latest News
Rare Disease Day 2026
Approximately 300 million people are living today with rare diseases. Neutropenia is a rare disease, but still it exists! All the Neutro-NARPS team and Working Groups Members join forces to better understand the pathophysiology and provide the best support for the diagnosis and treatment of patients living with neutropenia. Neutro-NARPS supports Rare Disease Day 2026!
International Day of Women and Girls in Science
On the International Day of Women and Girls in Science, we highlight Professor Papadaki’s leading role in research on neutropenia and bone marrow failure syndromes.
NEUTRO-NARPS 1st Working Groups Meeting Successfully Held
The NEUTRO-NARPS 1st Working Groups Meeting, held on 23rd January 2026, was completed with great success, bringing together more than 100 members from across the network in a highly engaging virtual event.
Open Call for Grants
Application Period 12/01/26 – 28/01/2026We would like to announce the first open call for Grants, funded by our COST Action NEUTRO-NARPS (CA24124): Read more..
Season’s Greetings
Happy Holidays and best wishes for a Happy New Year from all of us in NEUTRO-NARPS.Wishing you and your families peace, joy, and success.
It’s official!
Our COST ACTION’s kick-off meeting took place on Friday 24th Ocrober, in Brussels!What a fruitful day it was. Lots of discussions, brainstorming and plans for our future steps.So many familiar faces and new ones that we welcome to the neutropenia community.The journey has just begun. Stay tuned!!!
Kick-off Meeting
COST Action CA24124 – Network for the Advancement of Neutropenia Research and Patient Support (Neutro-NARPS) The Kick-off Meeting of the Neutro-NARPS (CA24124) Action will take place in Brussels, on October 24, 2025, at the COST Association Office. This marks the official launch of the Network for the Advancement of Neutropenia Research and Patient Support (Neutro-NARPS) […]
Get to Know Us & Connect with Neutro-NARPS
We are excited to welcome you to the official online presence of Neutro-NARPS – Network for the Advancement of Neutropenia Research and Patient Support (COST Action CA24124)! Neutro-NARPS is a European network of scientists, clinicians, patient representatives, and industry partners dedicated to improving the understanding, diagnosis, and treatment of Chronic Neutropenia (CNP) — a rare […]
Welcome to Neutro‑NARPS – COST Action CA24124
We are delighted to announce the launch of Neutro-NARPS (CA24124) – Network for the Advancement of Neutropenia Research and Patient Support, a new COST Association Action. The formal approval date was 19 May 2025 and the Action runs from 24 October 2025 until 23 October 2029. Who we are Neutro-NARPS brings together a multidisciplinary consortium […]
COST (European Cooperation in Science and Technology) is a funding agency for research and innovation networks. Our Actions help connect research initiatives across Europe and enable scientists to grow their ideas by sharing them with their peers. This boosts their research, career and innovation.
